Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2012 · 10-Q
Revenue$214.00K$214.00K+7.5% vs Q2 2011 Net Income-$29.08M-$29.08MN/M vs Q2 2011 EPS Diluted-$0.06-$0.06N/M vs Q2 2011 Operating Income-$28,624,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$21,531,000N/M Margins · derivedOperating margin-13375.7%−571.7 pt vs Q2 2011
Net margin-13588.8%−558.1 pt vs Q2 2011
ended Jun 30, 2013 · filed Aug 1, 2013 · 32 d after period end